BrainStorm Cell Therapeutics Inc (BCLI)

[sokol]

“Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.”

The biomarker information from the phase 3 clinical trial was favorable, indicating that NurOwn is eliciting a desired biological effect. This effect may “ultimately slow or stabilize disease progression.” So, what is meant or implied by “ultimately”? Is it that NurOwn may need to be administered for a more extended period to be useful for some patients? Does the data demonstrate that NurOwn is effective sooner for patients with earlier onset of the disease and that NurOwn, if effective at all, may slow or stabilize disease progression in those patients are farther along in the disease progression with more severe damage?